Download PDF
Nephrologie aktuell 2023; 27(03): 104-108
DOI: 10.1055/a-2008-1740
Expertentipp

Lupusnephritis: Therapieziel und -strategie

Systemerkrankungen
Julia Weinmann-Menke
› Further Information
Also available at
    Permissions and Reprints

Die Nierenbeteiligung bei systemischem Lupus erythematodes (SLE) ist mit einer Inzidenz von ca. 40–60 % eine der häufigsten Organmanifestationen. Die histologische Sicherung der Lupusnephritis (LN) und damit der LN-Klasse ist zurzeit der Goldstandard der Diagnosesicherung. Das Wissen über die LN-Klasse ist ein relevanter Bestandteil der adäquaten Therapieplanung bei Patienten mit LN. Hier ist insbesondere die frühe Diagnosestellung als auch das rasche Ansprechen auf die eingesetzten Therapien von prognostischer Bedeutung für den Erhalt der Nierenfunktion sowie die Morbidität und Mortalität der Patienten.



Publication History

Article published online:
14 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Anders HJ, Saxena R, Zhao MH. et al Lupus nephritis. Nat Rev Dis Primers 2020; 06: 7
    CrossrefPubMedSearch in Google Scholar
  • 2 Hanly JG, O‘Keeffe AG, Su L. et al The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 2016; 55: 252-262
    CrossrefPubMedSearch in Google Scholar
  • 3 Wilson PC, Kashgarian M, Moeckel G. Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis. Clin Kidney J 2018; 11: 207-218
    CrossrefPubMedSearch in Google Scholar
  • 4 Weening JJ, D’Agati VD, Schwartz MM. et al The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-250
    CrossrefPubMedSearch in Google Scholar
  • 5 Houssiau FA, Vasconcelos C, D’Cruz D. et al The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-64
    CrossrefPubMedSearch in Google Scholar
  • 6 Chan TM, Li FK, Tang CS. et al Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162
    CrossrefPubMedSearch in Google Scholar
  • 7 Appel GB, Contreras G, Dooley MA. et al Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112
    CrossrefPubMedSearch in Google Scholar
  • 8 Ginzler EM, Dooley MA, Aranow C. et al Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228
    CrossrefPubMedSearch in Google Scholar
  • 9 Tunnicliffe DJ, Palmer SC. Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review. Am J Kidney Dis 2018; 72: 756-757
    CrossrefPubMedSearch in Google Scholar
  • 10 Davidson A. The rationale for BAFF inhibition in systemic lupus erythematosus. Curr Rheumatol Rep 2012; 14: 295-302
    CrossrefPubMedSearch in Google Scholar
  • 11 Nashi E, Wang Y, Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol 2010; 42: 543-550
    CrossrefPubMedSearch in Google Scholar
  • 12 Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus. IUBMB Life 2012; 64: 595-602
    CrossrefPubMedSearch in Google Scholar
  • 13 Furie R, Rovin BH, Houssiau F. et al Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020; 383: 1117-1128
    CrossrefPubMedSearch in Google Scholar
  • 14 Rovin BH, Furie R, Teng YKO. et al A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 2022; 101: 403-413
    CrossrefPubMedSearch in Google Scholar
  • 15 Rovin BH, Teng YKO, Ginzler EM. et al Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2070-2080
    CrossrefPubMedSearch in Google Scholar
  • 16 Furie RA, Aroca G, Cascino MD. et al B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022; 81: 100-107
    CrossrefPubMedSearch in Google Scholar
  • 17 Weening JJ, D’Agati VD, Schwartz MM. et al The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-530
    CrossrefPubMedSearch in Google Scholar
  • 18 Fanouriakis A, Kostopoulou M, Cheema K. et al 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 2020; 79: 713-723
    CrossrefPubMedSearch in Google Scholar
  • 19 Moroni G, Vercelloni PG, Quaglini S. et al Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 2018; 77: 1318-1325
    CrossrefPubMedSearch in Google Scholar
  • 20 Malvar A, Alberton V, Lococo B. et al Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 2020; 97: 156-162
    CrossrefPubMedSearch in Google Scholar
  • 21 Jayne D, Bajema IM. “In my beginning is my end”: usefulness of repeat kidney biopsies in lupus nephritis. Kidney Int 2020; 97: 27-29
    CrossrefPubMedSearch in Google Scholar
  • 22 Moroni G, Gatto M, Tamborini F. et al Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 2020; 79: 1077-1083
    CrossrefPubMedSearch in Google Scholar
  • 23 Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021; 80: 14-25
    CrossrefPubMedSearch in Google Scholar